MetaCap

Aytu BioPharma (AYTU) vs Rein Therapeutics (RNTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aytu BioPharma (AYTU) has outperformed Rein Therapeutics (RNTX) over the past year, gaining 32.3% versus a loss of 77.2%. Over five years, AYTU leads with a -93.2% price change compared with -97.5% for RNTX. Rein Therapeutics is the larger company by market cap ($29.1 million vs $28.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AYTU+32.34%RNTX-77.24%
+50%-16%-83%
Nov 21, 20251 yearNov 20, 2026
AYTU-93.42%RNTX-97.57%
+5%-49%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AYTU versus RNTX key metrics
MetricAYTURNTX
Share price$2.66$0.3369
Market cap$28.91M$29.06M
1-day change0.00%-8.38%
YTD return+2.31%-70.96%
1-year return+32.34%-77.24%
5-year return-93.21%-97.47%
Forward P/E17.16—
EPS (TTM)$-1.78$-1.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$57.57M$0
Revenue growth (YoY)-13.27%—
Net income (latest FY)$-14.25M$-49.87M
Gross margin63.95%—
Operating margin-14.44%—
Net margin-24.76%—
52-week high$3.07$2.10
52-week low$1.75$0.284
Distance from 52-week high-13.36%-83.96%
Analyst consensusstrong_buynone
Avg. price target upside+263.53%+1680.94%
Average volume141.18K586.68K
Shares outstanding10.87M86.27M
Employees7510
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AYTU has outperformed RNTX by 109.6 percentage points over the past year.

About Aytu BioPharma

AYTU stock →

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

About Rein Therapeutics

RNTX stock →

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

AYTU vs RNTX FAQ

Which is bigger, Aytu BioPharma or Rein Therapeutics?

Rein Therapeutics (RNTX) is larger, with a market capitalization of $29.06M compared with $28.91M for Aytu BioPharma (AYTU).

Which stock has performed better over the past year, AYTU or RNTX?

AYTU returned +32.34% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.

Are Aytu BioPharma and Rein Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons